![\"CT](\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/04\/ct-lung-cancer-screening.jpg\")
Adherence rises six percentage points in two years<\/h2>\n
Published in JAMA Internal Medicine, the first study analyzed data from 26,100 people surveyed in the 2024 Behavioral Risk Factor Surveillance System (BRFSS), comparing them with the 2022 cohort. The result: up-to-date LDCT screening prevalence rose to 24% versus 18% two years earlier \u2014 a six-percentage-point increase. The gap between men and women narrowed to just half a percentage point, suggesting the gain was relatively gender-neutral.<\/p>\n
The 65\u201369 age group did most of the work, with adherence climbing to 33% \u2014 a nine-point jump over 2022. That is consistent with both Medicare eligibility and the logistical advantage of structured preventive care for that age band. Even so, lung screening still trails other cancer programs: breast (80%), cervical (75%) and colorectal (67%) all show much higher coverage.<\/p>\n
The uncomfortable finding: higher real-world mortality<\/h2>\n
The second study, published in JAMA Network Open, layers in further nuance. Researchers evaluated screening effectiveness within the U.S. Veterans Health Administration (VA), one of the more mature programs in the country. They compared 732 people screened in the VA cohort with NLST participants on five-year all-cause mortality.<\/p>\n
The numbers were sobering: VA mortality was 2.5 times higher than NLST (24% vs. 9.7%) and the adjusted hazard ratio reached 2.98. The authors note that, even though VA patients met the same NLST eligibility criteria, they were sicker at baseline, which limits how much long-term benefit they can extract from screening. In other words, formal eligibility criteria can mask clinical heterogeneity that changes the program’s real impact.<\/p>\n
Why this should reshape how we think about screening<\/h2>\n
NLST established back in 2011 that LDCT screening in heavy smokers cut lung cancer mortality by roughly 20% and all-cause mortality by about 7%. Based on that evidence, Medicare started reimbursing the exam in 2015. What these two new studies suggest is that extrapolating NLST findings directly into routine practice may overstate the benefit, especially in populations with heavier cardiovascular and respiratory comorbidity.<\/p>\n
That caveat applies both to the United States and to nascent programs elsewhere. Germany, for instance, is the most recent country to roll out organized population-based lung screening. In countries like Brazil, no public LDCT screening program exists yet, but private services and preventive medicine pathways have started offering the test for selected patients \u2014 always with the disclaimer that mortality gains depend on solid risk stratification and a defined workup pathway for suspicious nodules.<\/p>\n
Implications for radiology and imaging operations<\/h2>\n
For the radiologist working in screening, three operational points emerge from the new data. The first is the centrality of structured nodule classification \u2014 ideally Lung-RADS \u2014 with a clear follow-up pathway. The second is the growing role of AI for nodule volumetric quantification and for opportunistic findings such as coronary calcium, emphysema and interstitial disease, a discussion connected to incidental findings on chest CT<\/a>. The third is the need for structured reporting that enables fast, standardized comparison of serial exams.<\/p>\n From an operational standpoint, the VA findings underline that real-world benefit depends on clinical stratification and multidisciplinary coordination. A screening program that detects lesions but fails to move the patient to biopsy, staging and treatment loses most of the expected impact. For radiology services planning to scale LDCT volume, partnerships with pulmonology and oncology should come first, alongside PACS workflows that handle serial comparison cleanly \u2014 themes that also surface in research on interpretation efficiency in radiology<\/a>.<\/p>\n It is worth keeping the limitations in mind. The BRFSS study relies on self-report, which can overstate adherence. The VA cohort has its own profile \u2014 high prevalence of heavy smoking, comorbidity and distinct socioeconomic context \u2014 and may not represent the broader U.S. population. All-cause mortality is more conservative than cancer-specific mortality but also more sensitive to external factors such as cardiac disease and COPD.<\/p>\n The lesson for the field is to balance enthusiasm with prudence. Rising adherence is good news, but tracking real-world outcomes should be treated as a continuous improvement loop, not as a finished story.<\/p>\n The likely future combines three forces. First, the expansion of organized lung screening programs in more countries, with eligibility criteria tuned to actual risk rather than only age and pack-years. Second, the integration of AI for both detection and risk prediction based on lung patterns and opportunistic findings. Third, sharper clinical stratification before screening, incorporating comorbidities, life expectancy and treatment capacity.<\/p>\n That combination has the potential to lift quality-adjusted life years \u2014 the more relevant metric for health systems \u2014 rather than simply pushing exam volume. For health systems still designing their first programs, this is a useful window to define local protocols that ensure each exam ordered translates into a tangible clinical benefit.<\/p>\nThe limits of the numbers<\/h2>\n
Outlook: organized screening, AI and refined stratification<\/h2>\n